Publication: CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
Issued Date
2012-10-16
Resource Type
ISSN
11787066
Other identifier(s)
2-s2.0-84868143866
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmacogenomics and Personalized Medicine. Vol.5, No.1 (2012), 149-153
Suggested Citation
Ekaphop Sirachainan, Sureerat Jaruhathai, Narumol Trachu, Ravat Panvichian, Thitiya Sirisinha, Touch Ativitavas, Vorachai Ratanatharathorn, Montri Chamnanphon, Chonlaphat Sukasem CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients. Pharmacogenomics and Personalized Medicine. Vol.5, No.1 (2012), 149-153. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/13591
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
Other Contributor(s)
Abstract
Aim: We evaluated single nucleotide polymorphisms (SNPs) of CYP2D6 to identify those that influence the efficiency of tamoxifen in adjuvant treatment of breast cancer through a matched case-control study. Methods: Peripheral blood DNA was collected from 20 patients with disease recurrence during adjuvant tamoxifen treatment and from 19 patients who had completed 5 years of tamoxifen therapy without recurrence of breast cancer. CYP2D6*4 (1846G > A; rs3892097), CYP2D6*10 (100C > T, rs1065852), and CYP2D6*5 (deletion) were genotyped. The correlation between disease-free survival (DFS) and genotype and clinical outcome were assessed using Kaplan-Meier analysis and a log-rank test. Results: We found the allelic frequency of CYP2D6*10 during this study. Patients with the CYP2D6*10 homozygous variant T/T genotype had a significantly shorter median of DFS than those with C/T (P = 0.036), but DFS was not significantly different from that of patients with the C/C genotype (P = 0.316). One patient who was a carrier both of CYP2D6 G/A (1846G > A) and T/T (100C > T) had DFS of 22.7 months. Conclusions: This study demonstrated that CYP2D6*10/*10 was significantly associated with shorter DFS in Thai breast cancer patients receiving tamoxifen. This was a pilot study investigating the correlation of CYP2D6 polymorphisms and their influence on clinical outcomes in Thai estrogen receptor-positive breast cancer patients. © 2012 Sirachainan et al.